Tim van Hauwermeiren
Gründer bei ARGENX SE
Vermögen: 34 Mio $ am 30.04.2024
Profil
Tim van Hauwermeiren, Gründer der argenx SE, bekleidet derzeit die Position des Chairman von Aelin Therapeutics NV und des Chief Executive Officer & Executive Director bei argenx SE. Außerdem ist er im Vorstand von iTeos Therapeutics SA und iTeos Therapeutics, Inc. In der Vergangenheit hatte er die Position des Group Head bei Procter & Gamble Co. und des Senior Manager-Business Development bei Ablynx NV inne. Er erwarb einen MBA an der Vlerick Leuven Gent Management School sowie ein Diplom und einen Bachelor-Abschluss an der Universität Gent.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ARGEN-X SE
0,12% | 20.02.2024 | 71 986 ( 0,12% ) | 27 Mio $ | 30.04.2024 |
ARGENX SE ADR
0,03% | 31.08.2023 | 18 100 ( 0,03% ) | 7 Mio $ | 30.04.2024 |
ITEOS THERAPEUTICS, INC.
-.--% | 16.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Tim van Hauwermeiren
Unternehmen | Position | Beginn |
---|---|---|
ARGENX SE | Gründer | 01.01.2008 |
ITEOS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.06.2018 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Direktor/Vorstandsmitglied | 27.06.2018 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Vorsitzender | - |
Ehemalige bekannte Positionen von Tim van Hauwermeiren
Unternehmen | Position | Ende |
---|---|---|
RAYZEBIO, INC. | Direktor/Vorstandsmitglied | 26.02.2024 |
ABLYNX | Corporate Officer/Principal | - |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Ausbildung von Tim van Hauwermeiren
Vlerick Leuven Gent Management School | Masters Business Admin |
Ghent University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
ARGENX SE | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
ITEOS THERAPEUTICS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |